{"schema_version":"secwatch.filing_event.v1","accession":"0001711279-23-000074","form_type":"8-K","ticker":"KRYS","cik":"0001711279","company_name":"Krystal Biotech, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.137274+00:00","generated_at":"2026-06-08T21:12:15.661079+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Krystal Biotech reports first VYJUVEK revenue of $8.6M; net income $80.7M in Q3 2023","bullets":["VYJUVEK net product revenue $8.6M in Q3 2023; 284 Patient Start Forms from 136 prescribers; patient compliance 96%.","Net income $80.7M ($2.79 diluted EPS) vs net loss ($29.9M) year-ago; includes $100M gain on PRV sale.","Cash, equivalents and investments $598.6M; R&D expense $10.6M; SG&A $23.7M.","Pipeline: Cohort 1 complete in Phase 1 KB407 (CF); first patient dosed in Phase 1 KB707 (solid tumors); IND cleared for KB408 (AATD).","B-VEC filed for EU marketing authorization; Japan extension study dosed 5 patients; PRV sold for $100M; ASTRA facility operational."],"urls":{"canonical":"https://secwatch.observer/filing/0001711279-23-000074","json":"https://secwatch.observer/filing/0001711279-23-000074.json","markdown":"https://secwatch.observer/filing/0001711279-23-000074.md","text":"https://secwatch.observer/filing/0001711279-23-000074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/0001711279-23-000074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/krys-20231106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T21:12:15.661079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9b9645381cc5a6966a5a17fe8830604b3cbcdf6d","claim":"Krystal Biotech, Inc. reported financial results for the quarter ending September 30, 2023.","evidence_excerpt":"On November 6, 2023, Krystal Biotech, Inc., a Delaware corporation (the “Company”), announced its financial results for the quarter ending September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1711279/000171127923000074/0001711279-23-000074-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ending September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}